活性维生素D在实验性尿毒症中具有心脏保护作用,但在CKD 3-5期儿童中无此效应
该研究结合5/6肾切除大鼠模型与4C研究嵌套病例对照分析,探讨活性维生素D对尿毒症心脏重构的作用。大鼠中骨化三醇剂量依赖性减轻左室肥厚、纤维化并抑制心脏RAS;但CKD 3-5期儿童经活性维生素D治疗9个月后左室质量指数与未治疗组无差异,且FGF23和磷酸盐升高、sKlotho和eGFR降低。
要点
- 骨化三醇在5/6Nx大鼠中剂量依赖性改善左室肥厚、纤维化及心脏RAS激活
- CKD 3-5期儿童使用活性维生素D 9个月未改善左室质量指数
- 活性维生素D治疗与FGF23和磷酸盐升高、sKlotho和eGFR降低相关
核心结论
- 活性维生素D改善5/6Nx大鼠的心脏重构并纠正肾脏Klotho表达,但不改善CKD 3-5期儿童的心脏表型。
- 这一差异可能与治疗患者循环FGF23进一步升高及CKD进展更快(sKlotho降低、血磷升高)有关。
研究设计与样本
- 大鼠5/6肾切除模型给予骨化三醇,比较心脏表型与局部RAS激活。
- 在4C研究内进行嵌套病例对照研究,纳入CKD 3-5期儿童(eGFR 25 mL/min/1.73 m2),比较接受与未接受活性维生素D治疗者。
- 基线和9个月时评估超声心动图、血浆FGF23和可溶性Klotho。
主要发现
- 5/6Nx大鼠中骨化三醇剂量依赖性减轻左室肥厚、左室纤维化并下调上调的心脏RAS。
- 骨化三醇刺激骨骼而非心脏的FGF23合成,并使受抑制的肾脏Klotho表达正常化。
- 4C队列中活性维生素D治疗平均9个月与FGF23和磷酸盐升高、sKlotho和eGFR降低相关,而左室质量指数组间无差异。
临床怎么用
- 在CKD 3-5期儿童中,不应期待活性维生素D改善左室质量指数等心脏表型。
- 使用活性维生素D时需关注FGF23升高、血磷升高及eGFR下降和sKlotho降低的潜在风险。
局限性
- 动物模型结果不能直接外推至儿童CKD人群。
- 4C嵌套病例对照研究为观察性设计,治疗组与对照组基线特征可能存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uraemic cardiac remodelling is associated with vitamin D and Klotho deficiency, elevated fibroblast growth factor 23 (FGF23) and activation of the renin-angiotensin system (RAS). The cardioprotective properties of active vitamin D analogues in this setting are unclear. METHODS: In rats with 5/6 nephrectomy (5/6Nx) treated with calcitriol, the cardiac phenotype and local RAS activation were investigated compared with controls. A nested case-control study was performed within the Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study, including children with chronic kidney disease (CKD) Stages 3-5 [estimated glomerular filtration rate (eGFR) 25 mL/min/1.73 m2] treated with and without active vitamin D. Echocardiograms, plasma FGF23 and soluble Klotho (sKlotho) were assessed at baseline and after 9 months. RESULTS: In rats with 5/6Nx, left ventricular (LV) hypertrophy, LV fibrosis and upregulated cardiac RAS were dose-dependently attenuated by calcitriol. Calcitriol further stimulated FGF23 synthesis in bone but not in the heart, and normalized suppressed renal Klotho expression. In the 4C study cohort, treatment over a mean period of 9 months with active vitamin D was associated with increased FGF23 and phosphate and decreased sKlotho and eGFR compared with vitamin D naïve controls, whereas LV mass index did not differ between groups. CONCLUSIONS: Active vitamin D ameliorates cardiac remodelling and normalizes renal Klotho expression in 5/6Nx rats but does not improve the cardiac phenotype in children with CKD Stages 3-5. This discrepancy may be due to further enhancement of circulating FGF23 and faster progression of CKD associated with reduced sKlotho and higher serum phosphate in vitamin D-treated patients.
引用
- Schön A, Leifheit-Nestler M, Deppe J, et al. Active vitamin D is cardioprotective in experimental uraemia but not in children with CKD Stages 3-5. Nephrol Dial Transplant. 2021. PMID: 33241290. doi:10.1093/ndt/gfaa227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。